Our patients have spoken: “We want earlier diagnoses to stop disease progression and better biomarkers for earlier diagnosis”
On March 8th, 2017, the Arthritis Foundation, US Food and Drug Administration (FDA), osteoarthritis (OA) patients, drug developers, health care providers and academic researchers came together to discuss the serious burden of OA disease, particularly the most significant OA-related symptoms, the impact of those symptoms, currently available treatments and ideal treatments.
Continue reading Summary & Results from Osteoarthritis Patient-Focused Drug Development Meeting
“You are what you eat” is a phrase we often hear. But how true is it? Dr. Richard F. Loeser, Jr. and his research team are looking at the role of diet in their Arthritis Foundation-funded project “The Role of the Microbiome in Metabolic Osteoarthritis (OA)”.
Different factors play into why a person develops OA, including aging, injury, and being overweight. Diet plays an important role. What you eat can help influence what bacteria (or microbiota) live in your digestive track (gut). This, in turn, can influence what chemicals are released into your body. A healthy gut generally has a more diverse collection of helpful microbiota, while a microbial imbalance can lead to disease.
Continue reading Researchers on the Path to a Cure – Spotlight on Dr. Richard F. Loeser, Jr
Big things come in small packages, and Dr. Hongsik Cho is very familiar with this phenomenon. When we first introduced Dr. Cho in August 2016, he was beginning work on his 2-year Arthritis Foundation-funded project, “A Novel Method of Detecting and Treating Early PTOA Using Smart Nanosome”. He and his team are studying two things: a new drug and a new drug delivery system. The drug, called TPCA-1, works to prevent inflammation caused by post-traumatic osteoarthritis (PTOA). The drug delivery system uses small packets called nanosomes that contain TPCA-1 and a fluorescent dye that illuminates the nanosomes’ path once injected into mice.
Continue reading Researchers on the Path to a Cure – Spotlight on Dr. Hongsik Cho
Venom can kill, but this research proves it could help do the opposite. More specifically, some chemicals found in venom could act as a treatment for disease. These chemicals come from a deadly reptile, but with the help of Dr. Christine Beeton, venom might be able to better the lives of multitudes of people.
Dr. Beeton and her research team are looking at the chemicals found in scorpion venom as a source of potential treatment for autoimmune diseases like rheumatoid arthritis (RA).
Continue reading Researchers on the Path to a Cure – Spotlight on Dr. Christine Beeton
Earlier this year, we awarded funding to six scientists for projects submitted that show remarkable innovations and steps towards finding a cure for arthritis and related diseases. For the first time, we included patient input in selecting the projects that showed the most promise and meant the most to them.
Continue reading Arthritis Patients Help to Select Scientific Projects That Show Promise Towards Finding a Cure for Arthritis
What if injured joints could heal themselves before they develop osteoarthritis (OA)? Dr. James Martin’s current 3-year Arthritis Foundation-funded project, “Engineering Endogenous Cartilage Repair,” is trying to do just that- find ways to help joints heal before developing OA.
Dr. Martin and his team use special goats that have defects in areas of the thigh bones and cartilage, just above the knee. This closely mimics knee injuries that are seen in humans. The defects are surgically repaired with a hydrogel matrix that contains two important ingredients: repair cell attractant and growth factor. The repair cell attractant causes repair cells, called chondrogenic progenitor cells (CPCs), to migrate into the hydrogel. CPCs naturally occur in the cartilage. The growth factor, which is time-released over 10 days, causes the CPCs in the hydrogel to multiply and repair the injury with new cartilage.
Continue reading Researchers on the Path to a Cure – Spotlight on Dr. James Martin
This story started with a dozen male research mice survivors from hurricane Sandy in 2012. The storm devastated Dr. Bruce Cronstein’s research lab, but born from the destruction was Dr. Cronstein’s 5-year Arthritis Foundation Investigator-funded project, “The Role of Adenosine Receptors in Osteoarthritis.”
He described the damage: “Our labs were closed for nearly a year and a half. We lost a lot of our animal facilities. However, once a lot of the debris was cleared, we were able to go in and found that some of our mice had survived.”
Continue reading Researchers on the Path to a Cure – Spotlight on Dr. Bruce Cronstein
If you have osteoporosis you’ve probably heard of, and may have been treated with, a class of drugs that are used to prevent and treat bone loss: bisphosphonates. Dr. Tuhina Neogi and her research team are using new methods to look at how the long-term effects of using these drugs may be related to the progression of knee osteoarthritis (OA).
Dr. Neogi’s 2-year Arthritis Foundation-funded project, “Bisphosphonate Effects in Knee Osteoarthritis,” is looking at the relationship of bisphosphonate treatment and the structural changes in the knee associated with OA progression. To do this, Dr. Neogi and her team are looking at how knee joint space width, three-dimensional (3D) bone shape, and bone marrow lesions change in OA patients over time.
Continue reading Researchers on the Path to a Cure – Spotlight on Dr. Tuhina Neogi
What do skin and cartilage have in common? It depends on who you ask. Dr. Veronique Lefebvre, a researcher at Cleveland Clinic Lerner Research Institute, is currently working on a 2016 foundation-funded project called “Quality-by-Design approach to create articular cartilage from pluripotency” that connects the dots between skin and cartilage. Dr. Lefebvre and her team are developing a protocol that starts with skin cells and ends with knee cartilage.
Continue reading Researchers on the Path to a Cure – Spotlight on Dr. Veronique Lefebvre
Close to 200 patients, FDA staff, industry leaders, members of the media and academic personnel listened or participated in the groundbreaking Osteoarthritis Patient-Focused Drug Development meeting on March 8. The meeting was a forum for OA patients to share their experiences with the disease and talk about the signs and symptoms that matter most to them.
Continue reading Highlights from 2017 Osteoarthritis Patient-Focused Drug Development Meeting